PMID: 11899250Mar 20, 2002Paper

Coagulation factor Xa inhibition: biological background and rationale

Current Topics in Medicinal Chemistry
R J Leadley

Abstract

Ischemic heart disease and cerebrovascular disease are the leading causes of death in the world. Surprisingly, these diseases are treated by relatively antiquated drugs. However, due to our improved understanding of the underlying pathology of these diseases, and a number of technological advances in tools for drug discovery and chemical optimization, an exciting new wave of antithrombotic compounds is beginning to emerge in clinical trials. These agents, referred to as direct coagulation factor Xa inhibitors, appear to provide an enhanced risk-benefit margin compared to conventional therapy. Preclinical and early clinical data gathered over the past few years suggests that direct fXa inhibitors will provide the necessary advancements in efficacy, safety, and ease of use required to displace conventional therapy. Whether or not these agents will succeed will be determined as this class of agents advances through clinical trials in the near future. This review describes some of the key studies that sparked an interest in fXa as a therapeutic target, highlighting the findings that provided important rationale for continuing the development of potent and selective direct fXa inhibitors.

Citations

Feb 15, 2011·Journal of Thrombosis and Thrombolysis·Pancras C WongDonglu Zhang
Apr 5, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Kan HeScott J Grossman
Sep 19, 2003·The Journal of Surgical Research·Arthur J Chu, Suresh T Mathews
Jan 13, 2011·Thrombosis and Haemostasis·Alexander G G Turpie, Charles Esmon
Sep 4, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jacob L MuellerMariana F Wolfner
Oct 24, 2012·Leukemia & Lymphoma·Nitin JainKoen van Besien
Nov 18, 2008·Expert Opinion on Investigational Drugs·Jennifer Carreiro, Jack Ansell
Jul 25, 2006·Expert Opinion on Investigational Drugs·Dagmar Kubitza, Sylvia Haas
Jan 27, 2010·Bioorganic & Medicinal Chemistry Letters·Mimi L QuanRuth R Wexler
Jul 12, 2012·Thrombosis and Haemostasis·Daniella Gorete Lourenço OliveiraAna Marisa Chudzinski-Tavassi
Jul 16, 2008·Journal of Thrombosis and Haemostasis : JTH·T FurugohriT Shibano
Dec 8, 2009·Medicinal Research Reviews·Yu-Kai Lee, Mark R Player
Apr 19, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wenzhi WangChangjiang Huang
Nov 30, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Gianfranco LopopoloCosimo Altomare
Oct 19, 2010·Protein Engineering, Design & Selection : PEDS·Maria Rosario Fernandez-Fernandez, Begoña Sot
Jun 27, 2015·European Journal of Medicinal Chemistry·Jiabin YangYang Chen
Jun 13, 2003·Archives of Biochemistry and Biophysics·Arthur J ChuJulie Hoang
Mar 15, 2006·Bioorganic & Medicinal Chemistry·Jeffrey T KohrtJeremy J Edmunds
Jan 26, 2006·Bioorganic & Medicinal Chemistry Letters·Mimi L QuanRuth R Wexler
Sep 5, 2002·Biopolymers·A Bettio, A G Beck-Sickinger
Jul 14, 2004·Medicinal Research Reviews·Christos A Kontogiorgis, Dimitra Hadjipavlou-Litina
Feb 9, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Elisabeth PerzbornVolker Laux
Mar 8, 2005·Journal of Thrombosis and Haemostasis : JTH·E PerzbornA Straub
Dec 18, 2010·Nature Reviews. Drug Discovery·Elisabeth PerzbornFrank Misselwitz
Sep 12, 2009·Expert Opinion on Therapeutic Patents·Modesto de CandiaCosimo Altomare
Oct 12, 2011·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Tom J ParryBruce P Damiano
Nov 7, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Donglu ZhangKan He
Nov 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Pancras C WongRobert M Knabb
Nov 18, 2006·Genome Génome / Conseil National De Recherches Canada·W Evan BraswellWillie J Swanson
Apr 19, 2017·Oncotarget·Changjiang HuangLigong Chen
Sep 17, 2020·Expert Review of Cardiovascular Therapy·Omri CohenWalter Ageno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.